Telix Pharmaceuticals Shares Decline Following SEC Subpoena Investigation | Hagens Berman

SAN FRANCISCO, August 5, 2025 — Investors in Telix Pharmaceuticals Limited (NASDAQ: TLX) experienced a notable decrease in their share value after the company disclosed an SEC subpoena. The revelation prompted Hagens Berman, a national shareholder rights firm, to launch an inquiry into possible misstatements related to Telix's prostate cancer drug candidates. The investigation was initiated after Telix announced on July 22, 2025, that it was under SEC scrutiny concerning its disclosures about the development of certain therapeutic candidates. This news caused a sharp decline in the company's American Depositary Shares during trading hours on July 23. Hagens Berman is examining whether Telix may have provided misleading information regarding the progress and commercial potential of its treatments. The firm urges investors who have sustained significant losses or possess relevant information to come forward. Individuals with non-public insights are encouraged to consider the SEC Whistleblower Program, which offers rewards of up to 30% of any SEC recovery. For inquiries or to share information, contact Reed Kathrein at 844-916-0895 or via email at [email protected]. Hagens Berman sp...